Výsledky vyhledávání - "Gaurav Nigade"

Akademický článek

Real-World Experience with Nivolumab in Metastatic Renal Cell Carcinoma Patients Who Have Progressed on Prior Therapies: A Single-Center Study from India

Autor: Amit Rauthan, Nitin Yashas Murthy, Poonam Patil, Gaurav Nigade, SP Somashekhar, Shabber S. Zaveri

Publikováno v: South Asian Journal of Cancer, Vol 11, Iss 02, Pp 133-139 (2022)

Abstract Amit Rauthan Introduction Nivolumab monotherapy is approved for the treatment of metastatic renal cell carcinoma (mRCC) patients who have progressed on prior therapies based on the pivotal Checkmate-025 trial. There is limited literature o

Externí odkaz: https://doaj.org/article/764e9eb38daa4eb2a4fc19265d9cbded

Zobrazit plný text záznamu

120P Checkpoint inhibitors in responding patients with advanced carcinoma lung: Can we stop treatment? A single-center experience

Autor: P. Patil, Gaurav Nigade, A. Rauthan, R. Ashwath, N. Yashas, P. Vundemodalu

Publikováno v: Journal of Thoracic Oncology. 16:S763-S764

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::870da833a8b6e862bd0b5c8f352da7e1
https://doi.org/10.1016/s1556-0864(21)01962-6

Zobrazit plný text záznamu

84P Metastatic mismatch repair deficiency cancers: Hard to find, but a delight to treat!

Autor: Poonam Patil, C. Jomi, Gaurav Nigade, Shabber Zaveri, P. Vundemodalu, S. Sampige Prasannakumar, Amit Rauthan, R. Ashwath, Nitin Yashas Murthy

Publikováno v: Annals of Oncology. 32:S393

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::117787f8ae7e02125c0ce2a48e82c03a
https://doi.org/10.1016/j.annonc.2021.08.364

Zobrazit plný text záznamu

Abstract 4469: Impact of peripheral blood neutrophil lymphocyte ratio on response and survival in various malignancies treated with immunotherapy

Autor: Poonam Patil, Amit Rauthan, Shabber Zaveri, Rajshri Ashwath, Prathyush Vundemodalu, S.P. Somashekhar, Aditi Raghunathan, Kakoli Lahkar, K. Gupta, Gaurav Nigade, Nitin Yashas Murthy

Publikováno v: Cancer Research. 80:4469-4469

Introduction: Immune check point inhibitors(ICI) have revolutionized the treatment of metastatic malignancies. There is a need for a bio-marker apart from PDL-1 especially in a 2nd line setting in malignancies like metastatic renal cell carcinoma (mR

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::d42ce0794e40d5a929142f0c77408605
https://doi.org/10.1158/1538-7445.am2020-4469

Zobrazit plný text záznamu

Neutrophil-lymphocyte ratio as a prognostic marker in a resource constraint setting for metastatic malignancies treated with immune checkpoint inhibitors

Autor: Gaurav Nigade, Shabber Zaveri, Nitin Yashas Murthy, S. P. Somashekhar, K. Lahkar, T. Sood, S.S. Kulkarni, K. Gupta, Poonam Patil, Amit Rauthan

Publikováno v: Annals of Oncology. 30:xi5

Background There exists a need for a prognostic marker apart from PDL1 expression for patients being treated with immunotherapy. Neutrophil lymphocyte ratio (NLR) has been shown to correlate with outcomes in certain malignancies treated with immune c

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::287d9c11b19129ad312542afe2820d9d
https://doi.org/10.1093/annonc/mdz447.014

Zobrazit plný text záznamu

Immunotherapy with nivolumab in metastatic renal cell carcinoma in resource constraint settings: Impact of increasing intervals between standard doses, and stopping treatment early in responding patients

Autor: S.P. Somashekhar, Nitin Yashas, T. Sood, Amit Rauthan, S.S. Kulkarni, Shabber Zaveri, Poonam Patil, Gaurav Nigade

Publikováno v: Journal of Clinical Oncology. 37:e16078-e16078

e16078 Background: Nivolumab is now a standard 2nd line treatment for patients of metastatic Renal cell cancer (mRCC) who progress on 1st line Sunitinib or Pazopanib. Most western centers use Nivolumab for either 2 years duration, or indefinitely, or

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::22b73a9680f0483b1535034258c4a184
https://doi.org/10.1200/jco.2019.37.15_suppl.e16078

Zobrazit plný text záznamu

Immunotherapy with checkpoint inhibitors in mismatch repair deficient (dMMR) cancers: Looking for a needle in a haystack— But, joy on finding one

Autor: Poonam Patil, Shabber Zaveri, Gaurav Nigade, Nitin Yashas, Amit Rauthan, T. Sood, S.S. Kulkarni, S.P. Somashekhar

Publikováno v: Journal of Clinical Oncology. 37:e14073-e14073

e14073 Background: Pembrolizumab is approved for deficient mismatch repair (dMMR) or high microsatellite instability (MSI-H) metastatic solid tumors with objective response rate (ORR) of 39.6% and response lasting for more than 6 months in 78% patien

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::97523e148f159d1b45f6b78f191920c6
https://doi.org/10.1200/jco.2019.37.15_suppl.e14073

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání